Who
Pavel Raifeld
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Innoviva.
In numbers
- Trades disclosed
- 22
- Buys
- 1
- Sells
- 0
- Bought
- $33K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 21 May 2021
- Last trade
- 20 Aug 2026
- Last filed
- 24 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 24 Aug 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $24K1,130 at $21.00 | filing |
| 20 Aug 2026filed 24 Aug 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $24K1,130 at $21.00 | filing |
| 20 May 2026filed 22 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $25K1,130 at $22.24 | filing |
| 20 May 2026filed 22 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $25K1,130 at $22.24 | filing |
| 15 May 2026filed 22 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —1,123 at $0.00 | filing |
| 15 May 2026filed 22 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —1,123 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —126,646 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —312,500 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —312,500 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —126,646 at $0.00 | filing |
| 20 Feb 2026filed 24 Feb 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $70K2,986 at $23.39 | filing |
| 20 Feb 2026filed 24 Feb 2026 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code F | $70K2,986 at $23.39 | filing |
| 3 Nov 2025filed 5 Nov 2025 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | $2.0M110,436 at $18.11 | filing |
| 15 May 2025filed 5 Nov 2025 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | —1,860 at $0.00 | filing |
| 14 Mar 2025filed 26 Mar 2025 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —243,750 at $0.00 | filing |
| 14 Mar 2025filed 26 Mar 2025 | INVA InnovivaPharmaceuticals | SEC FORM 4 Code A | $650K37,377 at $17.39 | filing |
| 5 Mar 2024filed 7 Mar 2024 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Mar 2024filed 7 Mar 2024 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 5 Mar 2024filed 7 Mar 2024 | INVA Innovivaoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 10 Mar 2023filed 14 Mar 2023 | INVA InnovivaPharmaceuticals | SEC FORM 4 Bought | $33K3,000 at $10.87 | filing |
News
No headline names them, or the companies they trade most, lately.